SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. The company provides orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone760-727-8399
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$143.44 million
Profitability
Miscellaneous
Employees361
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable
SeaSpine (NASDAQ:SPNE) Frequently Asked Questions
What is SeaSpine's stock symbol?
SeaSpine trades on the NASDAQ under the ticker symbol "SPNE."
How were SeaSpine's earnings last quarter?
SeaSpine Holdings Corp (NASDAQ:SPNE) released its earnings results on Tuesday, October, 29th. The medical equipment provider reported ($0.51) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.43) by $0.08. The medical equipment provider earned $39.89 million during the quarter, compared to the consensus estimate of $38.48 million. SeaSpine had a negative return on equity of 27.36% and a negative net margin of 26.22%. View SeaSpine's Earnings History.
When is SeaSpine's next earnings date?
What price target have analysts set for SPNE?
3 Wall Street analysts have issued twelve-month price targets for SeaSpine's stock. Their forecasts range from $20.00 to $22.00. On average, they anticipate SeaSpine's stock price to reach $21.33 in the next twelve months. This suggests a possible upside of 64.6% from the stock's current price. View Analyst Price Targets for SeaSpine.
What is the consensus analysts' recommendation for SeaSpine?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SeaSpine in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SeaSpine.
What are Wall Street analysts saying about SeaSpine stock?
Here are some recent quotes from research analysts about SeaSpine stock:
- 1. According to Zacks Investment Research, "SeaSpine Holdings Corporation is a medical technology company which focused on the design, development and commercialization of surgical solutions for the treatment of spinal disorders. The company also offers orthobiologics and spinal fusion hardware solutions. SeaSpine Holdings Corporation is headquartered in Vista, California. " (11/2/2019)
- 2. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and $22 PT on SPNE. The strong execution that drove double-digit growth in 2H18 carried over into 2019 as SPNE posted 1Q revenue of $36MM (+9%), beating FactSet consensus by ~ $1MM, despite one less selling day, which we estimate likely created a 150bp headwind. SPNE is executing on its plan to add more exclusive distributors, increase proportion of revenue from recently launched products and progress against plan for staged launch of new products. SPNE raised the lower end of its 2019 sales guidance to $154-156MM (+7.5-9%), but we still consider guidance conservative and would not be surprised to see more beat and raises." (5/2/2019)
- 3. BTIG Research analysts commented, "We reiterate our Buy rating and $20 PT on SPNE following investor meetings in New York. High level takeaways from meetings noted an encouraging cadence of new product introductions in FY19 and beyond, a growing proportion of committed and exclusive distributors supporting SPNE’s portfolio, access to capital (without the need for additional funds in the next 3 years), achievable guidance, and an inexpensive valuation (absolute and relative). While 1Q is typically a seasonally softer quarter in spine, the outlook for FY19 is encouraging and if 2H18 is indicative of the momentum SPNE is seeing amongst its distributors and customers then a few more quarters of consistent execution should have shares re-rating at an improved multiple. We like SPNE’s set-up in FY19 as all the key pieces are in place for improved and continued momentum." (3/31/2019)
Has SeaSpine been receiving favorable news coverage?
Press coverage about SPNE stock has trended positive on Thursday, according to InfoTrie Sentiment. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. SeaSpine earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned media headlines about the medical equipment provider a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for SeaSpine.
Are investors shorting SeaSpine?
SeaSpine saw a decline in short interest in the month of October. As of October 15th, there was short interest totalling 134,800 shares, a decline of 6.1% from the September 15th total of 143,600 shares. Based on an average daily trading volume, of 45,500 shares, the days-to-cover ratio is currently 3.0 days. Currently, 0.9% of the company's shares are short sold. View SeaSpine's Current Options Chain.
Who are some of SeaSpine's key competitors?
Some companies that are related to SeaSpine include Luminex (LMNX), Cryolife (CRY), Anika Therapeutics (ANIK), Orthofix Medical (OFIX), Axonics Modulation Technologies (AXNX), LeMaitre Vascular (LMAT), Antares Pharma (ATRS), Intersect ENT (XENT), Cerus (CERS), Orthopediatrics (KIDS), AngioDynamics (ANGO), SurModics (SRDX), OraSure Technologies (OSUR), SI-Bone (SIBN) and Alphatec (ATEC).
What other stocks do shareholders of SeaSpine own?
Who are SeaSpine's key executives?
SeaSpine's management team includes the folowing people:
- Mr. Keith C. Valentine, Pres, CEO & Director (Age 51)
- Mr. John J. Bostjancic, Sr. VP, CFO & Treasurer (Age 48)
- Mr. Patrick L. Keran, VP, Gen. Counsel & Corp. Sec. (Age 47)
- Carrie Mendivil, Head of Investor Relations
- Mr. John J. Winge, VP of Sales (Age 52)
Who are SeaSpine's major shareholders?
SeaSpine's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Russell Investments Group Ltd. (4.16%), Mackay Shields LLC (0.55%), Essex Investment Management Co. LLC (0.54%), Monarch Partners Asset Management LLC (0.27%), Rhumbline Advisers (0.13%) and Commonwealth Equity Services LLC (0.11%). Company insiders that own SeaSpine stock include John B Henneman III, Keith Bradley, Richard E Caruso and Stuart Essig. View Institutional Ownership Trends for SeaSpine.
Which institutional investors are selling SeaSpine stock?
SPNE stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Mackay Shields LLC, Essex Investment Management Co. LLC, California Public Employees Retirement System and Assenagon Asset Management S.A.. Company insiders that have sold SeaSpine company stock in the last year include Richard E Caruso and Stuart Essig. View Insider Buying and Selling for SeaSpine.
Which institutional investors are buying SeaSpine stock?
SPNE stock was acquired by a variety of institutional investors in the last quarter, including Monarch Partners Asset Management LLC, Commonwealth Equity Services LLC and Rhumbline Advisers. View Insider Buying and Selling for SeaSpine.
How do I buy shares of SeaSpine?
Shares of SPNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is SeaSpine's stock price today?
One share of SPNE stock can currently be purchased for approximately $12.96.
How big of a company is SeaSpine?
SeaSpine has a market capitalization of $247.11 million and generates $143.44 million in revenue each year. The medical equipment provider earns $-33,520,000.00 in net income (profit) each year or ($2.18) on an earnings per share basis. SeaSpine employs 361 workers across the globe.View Additional Information About SeaSpine.
What is SeaSpine's official website?
How can I contact SeaSpine?
SeaSpine's mailing address is 5770 ARMADA DRIVE, CARLSBAD CA, 92008. The medical equipment provider can be reached via phone at 760-727-8399 or via email at [email protected]
MarketBeat Community Rating for SeaSpine (NASDAQ SPNE)
MarketBeat's community ratings are surveys of what our community members think about SeaSpine and other stocks. Vote "Outperform" if you believe SPNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPNE will underperform the S&P 500 over the long term. You may vote once every thirty days.
